Company Overview and News

4
Amgen Looks To Enter Multiple Myeloma Space: Can It Compete?

2018-09-11 seekingalpha
Amgen announces positive preliminary results using its antibody drug known as AMG 420, which is derived from the anti-BCMA BiTE program.
AMGN BLUE CELG BLUE

3
Upcoming Earnings to Watch: KR, PLAY, TLRD

2018-09-07 zacks
Second quarter earnings season saw another robust period of upside surprises and bottom-line growth, but tepid guidance in certain industries and external issues like trade disputes kept gains at bay. Now, as we move into a quiet period for earnings, thesame external factors will weigh on the minds of investors, and those reporting during this stretch will need to seriously impress.
BLUE TLRD

9
bluebird (BLUE) Reports Updated Data on Lenti-D Gene Therapy

2018-09-06 zacks
bluebird bio, Inc. (BLUE - Free Report) announced updated results from phase II/III Starbeam study (ALD-102) of its investigational Lenti-D gene therapy in boys aged 17 years or below with cerebral adrenoleukodystrophy (CALD). The company also announced initial results from the ongoing observational ALD-103 study of outcomes from allogeneic hematopoietic stem cell transplant (allo-HSCT) in boys aged 17 years or below with CALD.
CELGZ GILD BLUE LGNDZ TJX LGNZZ CELG LGND KHC LGNYZ LGNXZ BLUE

14
Software and Biotech Are Eating the World

2018-08-30 zacks - 1
There is no doubt that software stocks are on fire, igniting new highs for the stock market. And if the valuations were untouchable a year ago, they are definitely too hot to handle now.
WFC WFCNP SQ ULH BLUE CRSP NVDA SCVL BLUE BOOT

2
IPO Biotech Preview: Gritstone Oncology

2018-08-27 seekingalpha
Gritstone Oncology is gearing up for its $80 million IPO, and its prospects are highly promising.
BLUE BLUE

13
Your Cancer Research Highlight: Bristol-Myers Looks For An In To Earlier Multiple Myeloma

2018-08-24 seekingalpha
Bristol-Myers has finally gotten out a new application for approval for its relatively small Empliciti franchise.
AMGN BLUE CELG ABBV BLUE ABBV

12
bluebird bio: Heading To $200 On Pipeline Progress And Potential M&A

2018-08-22 seekingalpha - 1
bluebird bio is a clinical-stage biotechnology company focussed on gene therapy, cancer immunopathy and gene editing for the treatment of cancer and rare diseases.
MBIO REGN GILD JUNO BLUE CELG NVS KITE BLUE CR

7
Is Celgene Set to See Improved Results in the Second Half?

2018-08-21 zacks
Shares of Celgene Corporation (CELG - Free Report) have gained 18.6% in the last three months compared with growth of 4.3% for the industry.
XLRN CELGZ JUNO BLUE CELG BLUE LVS

8
Biotech Stock Roundup: Regeneron Shines, BLUE Surges, ONCE Plunges

2018-08-08 zacks
The key headlines in the biotech sector this week include Regeneron Pharmaceuticals’ (REGN - Free Report) strong Q2 results and its $100 million investment in bluebird bio (BLUE - Free Report) . Meanwhile, among regular pipeline and regulatory updates, Gilead (GILD - Free Report) is making further inroads into China with its HIV franchise.
VRTX REGN ELY ICFI BLUE BLUE ONCE

37
T-Mobile-Sprint, Pepsi CEO Departs, Jamie Dimon's Latest Wisdom, & More | Free Lunch

2018-08-06 zacks
On today’s episode of Free Lunch, Associate Stock Strategist Ryan McQueeney highlights today’s trending stories, including the departure of PepsiCo’s CEO, Jamie Dimon’s latest public wisdom, and Bluebird Bio’s new partnership. Later, he recaps recent developments in the T-Mobile-Sprint merger and previews what the combined company might look like.
REGN S PEP BLUE BLUE GTLS

2
Why Is Bluebird Bio (BLUE) Stock Gaining Today?

2018-08-06 zacks
Shares of Bluebird Bio (BLUE - Free Report) gained in morning trading Monday after the company announced a new partnership with Regeneron Pharmaceuticals (REGN - Free Report) . The five-year agreement will see both firms collaborate on new cell therapies for the treatment of cancer.
REGN BLUE BLUE

5
bluebird (BLUE) Q2 Loss Wider Than Expected, Revenues Miss

2018-08-03 zacks
bluebird bio, Inc. (BLUE - Free Report) reported a loss of $2.91 per share, much wider than the Zacks Consensus Estimate of a loss of $2.30 and the year-ago loss of $1.73. The wider-than-expected loss was due to higher research & development (R&D) and general & administrative (G&A) expenses on lower revenues.
CELGZ BLUE CELG NVS BLUE

8
What's in the Cards for Humana (HUM) Stock in Q2 Earnings?

2018-07-30 zacks
Humana Inc.’s (HUM - Free Report) second-quarter 2018 results, scheduled to be reported on Aug 1, 2018, has likely witnessed an increase in individual Medicare Advantage membership strength, driven by strong segmental performances. Additionally, the company has likely expanded into different geographical regions of their value-based primary care and Management Services Organization (MSO) support models.
ETR ALGN XRAY BLUE BLUE HUM AQB

19
What's in Store for Celldex (CLDX) This Earnings Season?

2018-07-30 zacks - 2
Celldex Therapeutics, Inc. (CLDX - Free Report) is expected to report second-quarter 2018 results on Aug 14.
BLUE CLDX BLUE BDSI

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Silicon Investor Message Boards

This table lists all message boards related to EPA:BLUE / BLUE on message board site Silicon Investor.

Daily Bluegrass Daily Bluegrass Daily Bluegrass Blue Eyes Crying in the Rain Blue Eyes Crying in the Rain Blue Eyes Crying in the Rain
bluebird bio Inc. bluebird bio Inc. bluebird bio Inc. Blueprint Medicines Blueprint Medicines Blueprint Medicines
BTV.V - Bluerush Media Group BTV.V - Bluerush Media Group BTV.V - Bluerush Media Group Blue Coat Inc. Blue Coat Inc. Blue Coat Inc.
Blue Chip Gold Stocks HM, NEM, ASA, ABX, PDG Blue Chip Gold Stocks HM, NEM, ASA, ABX, PDG Blue Chip Gold Stocks HM, NEM, ASA, ABX, PDG Blue Water Global Group Inc. Blue Water Global Group Inc. Blue Water Global Group Inc.
MIDNIGHT BLUES CAFE MIDNIGHT BLUES CAFE MIDNIGHT BLUES CAFE Blue Chip Gold Stocks HM, NEM, ASA, ABX, PDG (MODERATED) Blue Chip Gold Stocks HM, NEM, ASA, ABX, PDG (MODERATED) Blue Chip Gold Stocks HM, NEM, ASA, ABX, PDG (MODERATED)